Literature DB >> 1802490

Tumour necrosis factor alpha and interleukin-2 in plasma from rheumatoid arthritis patients in relation to disease activity.

G T Espersen1, M Vestergaard, E Ernst, N Grunnet.   

Abstract

Tumour necrosis factor alpha (TNF alpha) and interleukin-2 (IL-2) are potential immunological mediators of pathogenetic changes in rheumatoid arthritis. We measured the concentrations of TNF alpha and IL-2 in plasma from 2 groups of patients suffering from rheumatoid arthritis (RA). One group had high and one had low disease activity. In addition, in connection with steroid treatment in the high disease activity group, TNF alpha was significantly increased in plasma from RA patients with high disease activity compared with those of low disease activity (p = 0.0009). Furthermore, TNF alpha decreased significantly in relation to steroid medication, parallel to clinical improvement (p = 0.016). All IL-2 concentration measurements were within the estimated normal range. The increased TNF alpha plasma levels in patients with rheumatoid arthritis with high disease activity, might result from activated white mononuclear cells in the inflamed joints. This might, in part, support the theory that TNF alpha is a possible mediator of pathogenetic changes known to occur in rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1802490     DOI: 10.1007/BF02206655

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  13 in total

Review 1.  Peptide regulatory factors in non-malignant disease.

Authors:  G W Duff
Journal:  Lancet       Date:  1989-06-24       Impact factor: 79.321

Review 2.  The interleukins in acquired disease.

Authors:  M Malkovský; P M Sondel; W Strober; A G Dalgleish
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

Review 3.  The T cell system in rheumatoid arthritis: activated or defective?

Authors:  G D Kitas; M Salmon; I M Allan; P A Bacon
Journal:  Scand J Rheumatol Suppl       Date:  1988

Review 4.  Immune hormones (cytokines); pathogenic role in autoimmune rheumatic and endocrine diseases.

Authors:  K Bendtzen
Journal:  Autoimmunity       Date:  1989       Impact factor: 2.815

Review 5.  Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis.

Authors:  W P Arend; J M Dayer
Journal:  Arthritis Rheum       Date:  1990-03

6.  Tumour necrosis factor activity in joint fluids from rheumatoid arthritis patients.

Authors:  M L Neale; B D Williams; N Matthews
Journal:  Br J Rheumatol       Date:  1989-04

7.  Interleukin-2 in rheumatoid arthritis: production of and response to interleukin-2 in rheumatoid synovial fluid, synovial tissue and peripheral blood.

Authors:  B Combe; R M Pope; M Fischbach; B Darnell; S Baron; N Talal
Journal:  Clin Exp Immunol       Date:  1985-03       Impact factor: 4.330

8.  Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint.

Authors:  E R Pettipher; G A Higgs; B Henderson
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

9.  Interleukin-1 induces interleukin-1 alpha and interleukin-1 beta gene expression in synovial fibroblasts and peripheral blood monocytes.

Authors:  B J Dalton; J R Connor; W J Johnson
Journal:  Arthritis Rheum       Date:  1989-03

10.  Tumor necrosis factor and disease severity in children with falciparum malaria.

Authors:  G E Grau; T E Taylor; M E Molyneux; J J Wirima; P Vassalli; M Hommel; P H Lambert
Journal:  N Engl J Med       Date:  1989-06-15       Impact factor: 91.245

View more
  8 in total

1.  PAR(2) expression in peripheral blood monocytes of patients with rheumatoid arthritis.

Authors:  A Crilly; E Burns; M B Nickdel; J C Lockhart; M E Perry; P W Ferrell; D Baxter; J Dale; L Dunning; H Wilson; J S Nijjar; J A Gracie; W R Ferrell; I B McInnes
Journal:  Ann Rheum Dis       Date:  2012-01-30       Impact factor: 19.103

2.  Identification of genomic targets downstream of p38 mitogen-activated protein kinase pathway mediating tumor necrosis factor-alpha signaling.

Authors:  Cindy Zer; George Sachs; Jai Moo Shin
Journal:  Physiol Genomics       Date:  2007-07-24       Impact factor: 3.107

3.  Interleukin-2 production in early rheumatoid arthritis.

Authors:  H G Taylor; N B Nixon; P T Dawes
Journal:  Clin Rheumatol       Date:  1993-06       Impact factor: 2.980

4.  Tryptophan degradation and neopterin levels in treated rheumatoid arthritis patients.

Authors:  Yesim Ozkan; Guray Mete; Aylin Sepici-Dincel; Vesile Sepici; Bolkan Simsek
Journal:  Clin Rheumatol       Date:  2011-05-10       Impact factor: 2.980

5.  Decreased interleukin-1 beta levels in plasma from rheumatoid arthritis patients after dietary supplementation with n-3 polyunsaturated fatty acids.

Authors:  G T Espersen; N Grunnet; H H Lervang; G L Nielsen; B S Thomsen; K L Faarvang; J Dyerberg; E Ernst
Journal:  Clin Rheumatol       Date:  1992-09       Impact factor: 2.980

6.  Serum cytokines in patients with rheumatoid arthritis. Correlation of interferon gamma and tumor necrosis factor alpha with the characteristics of peripheral blood mononuclear cells.

Authors:  S Sakito; Y Ueki; K Eguchi; Y Kawabe; S Nagataki
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

7.  Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis.

Authors:  Tsutomu Takeuchi; Nobuyuki Miyasaka; Yoshihiko Tatsuki; Toshiro Yano; Toru Yoshinari; Tohru Abe; Takao Koike
Journal:  Ann Rheum Dis       Date:  2011-04-08       Impact factor: 19.103

8.  Reduced B lymphoid kinase (Blk) expression enhances proinflammatory cytokine production and induces nephrosis in C57BL/6-lpr/lpr mice.

Authors:  Elizabeth M Samuelson; Renee M Laird; Amber M Papillion; Arthur H Tatum; Michael F Princiotta; Sandra M Hayes
Journal:  PLoS One       Date:  2014-03-17       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.